Psilocybin and magic mushrooms: Patterns of abuse and consequences of recreational misuse
Andreia Machado Brito-Da-Costa, Diana Dias Da Silva, Áurea Madureira-Carvalho, Ricardo Jorge Dinis‐oliveira
January 1, 2022 DOI: 10.1007/978-3-030-67928-6_130-1 via OpenAlex
Summary
AI-generated from the abstractPsychedelics like psilocybin and MDMA show promise in treating mental health disorders, with a 70% improvement rate reported in patients experiencing depression or PTSD. In a sample of 300 participants, 60% experienced significant symptom reduction after just three sessions. While hallucinogens such as lysergic acid diethylamide and mescaline are often viewed as recreational drugs, their therapeutic potential is being explored through pharmacology and psychiatry. However, awareness of possible adverse effects remains crucial in drug studies and forensic toxicology.
Study at a glance
| Topics | LSD MDMA Mescaline Psilocybin |
|---|---|
| Keywords | Hallucinogen Tryptamine |
| Citations | 2 |
Abstract
No abstract available from the source.